2011年至2016年成都地区21家医院抗肿瘤抗生素类药物使用分析  

Analysis on Utilization of Antitumor Antibiotics in 21 Hospitals in Chengdu City from 2011 to 2016

作　　者：曾勇[1] 苏先旭[1] 孙嘉婧[1] 黄梦君[1] Zeng Yong;Su Xianxu;Sun Jiajing;Huang Mengjun(Dujiangyan People＇s Hospital,Chengdu,Sichuan,China 611830)

机构地区：[1]四川省都江堰市人民医院,四川成都611830

出　　处：《中国药业》2018年第21期86-88,共3页China Pharmaceuticals

摘　　要：目的了解2011年至2016年成都地区医院抗肿瘤抗生素类药物的使用情况及变化趋势。方法统计、分析2011年至2016年成都地区21家样本医院抗肿瘤抗生素类药物的使用金额、用药频度(DDDs)、日均费用(DDC)等。结果使用金额分别为2 251. 04万元、2 191. 02万元、2 275. 74万元、2 058. 67万元、2 123. 04万元、1 996. 26万元;表柔比星的DDDs最高,伊达比星DDC最高。结论成都地区医院抗肿瘤抗生素类药物的使用合理,符合安全、有效、经济、方便原则。Objective To investigate the current situations and trend of antitumor antibiotics used in 21 hospitals in Chengdu city from 2011 to 2016. Methods The use of antitumor antibiotics in 21 hospitals in Chengdu city from 2011 to 2016 were comprehensively analyzed by consumption sum, DDDs and DDC. Results From 2011 to 2016, the consumption sum of antitumor antibiotics used in Chengdu city was 2 251.04 million Yuan, 2 191.02 million Yuan, 2 275.74 million Yuan, 2 058.67 million Yuan, 2 123.04 million Yuan, 1 996. 26 million Yuan respectively. Epirubicin＇s DDDs was the highest, while Idarubicin＇s DDC was the highest. Conclusion The utilization of antitumor antibiotics in the hospitals in Chengdu city is reasonable, which accords with the principle of safety, effectivehess, eeonomy and eonven^enee.

关 键 词：抗肿抗生素 使用金额 用药频度 日均费用 合理用药 

分 类 号：R969.3[医药卫生—药理学] R979.14[医药卫生—药学]